Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2012

View Archived Issues

Kyowa Hakko Kirin reviews accomplishments of 2011

RNA-loaded dendritic cell vaccine shows promise combined with sunitinib

EpiCept seeks fast track designation for AmiKet

African sleeping sickness drug shows potential to treat leishmaniasis

Foretinib shows promise in large papillary renal cell carcinoma study

New vaccines for human papillomavirus prepared in China

Artificial Cell Technologies patents novel RSV vaccines

New phase I safety data presented on stroke therapy

Scientists at Calmune prepare novel antibodies for RSV infection

Bradykinin B1 receptor antagonist reduces pain in vivo

Vertex Pharmaceuticals claims novel HCV NS5B inhibitors

Rib-X Pharmaceuticals receives milestone payment under RX-04 collaboration

Amicus receives grant for Pompe's disease program

Japanese authorities remove condition for approval of Tarceva in NSCLC

Merck & Co. recaps milestones of fourth quarter and full year 2011

Erivedge launched in U.S.

Alexion Pharmaceuticals completes acquisition

FDA sets date for crofelemer NDA

Phase II study of ziprasidone commences in Japan

Line extension for Vyvanse in U.S.

Omeros provides update on phase III OMS-302 trial

Bio-Path completes treatment of second cohort in BP-100-1.01 study

Health Canada approves ipilimumab

FDA grants priority review for pertuzumab

Orion plans new studies of inhalable budesonide/formoterol combination

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...